Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Biol. Res ; 48: 1-9, 2015. ilus, graf
Article in English | LILACS | ID: biblio-950823

ABSTRACT

BACKGROUND: Theoretically human embryonic stem cells (hESCs) have the capacity to self-renew and differentiate into all human cell types. Therefore, the greatest promise of hESCs-based therapy is to replace the damaged tissues of patients suffering from traumatic or degenerative diseases by the exact same type of cells derived from hESCs. Allo-graft immune rejection is one of the obstacles for hESCs-based clinical applications. Human leukocyte antigen (HLA) II leads to CD4+ T cells-mediated allograft rejection. Hence, we focus on optimizing hESCs for clinic application through gene modification. RESULTS: Transcription activator-like effector nucleases (TALENs) were used to target MHC class II transactivator (CIITA) in hESCs efficiently. CIITA(-/-)hESCs did not show any difference in the differentiation potential and self-renewal capacity. Dendritic cells (DCs) derived from CIITA(-/-)hESCs expressed CD83 and CD86 but without the constitutive HLA II. Fibroblasts derived from CIITA(-/-)hESCs were powerless in IFN-γ inducible expression of HLA II. CONCLUSION: We generated HLA II defected hESCs via deleting CIITA, a master regulator of constitutive and IFN-γ inducible expression of HLA II genes. CIITA(-/-)hESCs can differentiate into tissue cells with non-HLA II expression. It's promising that CIITA(-/-)hESCs-derived cells could be used in cell therapy (e.g., T cells and DCs) and escape the attack of receptors' CD4+ T cells, which are the main effector cells of cellular immunity in allograft.


Subject(s)
Humans , Animals , Mice , Nuclear Proteins/genetics , Trans-Activators/genetics , Cell Differentiation/genetics , Gene Deletion , Deoxyribonucleases/metabolism , Human Embryonic Stem Cells/metabolism , Teratoma , Dendritic Cells/metabolism , Immunoglobulins/metabolism , Immunohistochemistry , Membrane Glycoproteins/metabolism , Tumor Cells, Cultured , Histocompatibility Antigens Class II/genetics , Antigens, CD/metabolism , Interferon-gamma/metabolism , Mice, SCID , Reverse Transcriptase Polymerase Chain Reaction , Deoxyribonucleases/classification , B7-2 Antigen/metabolism , Embryoid Bodies/metabolism , Real-Time Polymerase Chain Reaction , Karyotype , Fibroblasts/metabolism , Cell Self Renewal , Antigen-Presenting Cells/metabolism
2.
IBJ-Iranian Biomedical Journal. 2011; 15 (1,2): 1-5
in English | IMEMR | ID: emr-129770

ABSTRACT

During antigen capture and processing, mature dendritic cells [DC] express large amounts of peptide-MHC complexes and accessory molecules on their surface. DC are antigen-presenting cells that have an important role in tolerance and autoimmunity. The transforming growth factor-beta 1 [TGF-beta1] cytokine has a regulatory role on the immune and non-immune cells. The aim of this study is to evaluate the effect of TGF-beta1 on the induction of human leukocyte antigen-G [HLA-G] expression on the DC which is derived from monocyte. Methods: In this study, we evaluated the effect of TGF-beta1 in induction HLA-G expression on the monocyte-derived DC by flowcytometry and then CD4[+] T cell proliferative responses in the presence of DC-treated TGF-[beta1] was studied. Results: The results of this study showed that DC bearing HLA-G down-regulated activation of CD4[+] T cells and production of IL-6 and IL-17 in comparison with control [P<0.05]. Conclusion: It is concluded that TGF-beta1 has an important regulatory role in CD4[+] T cell proliferation by increasing HLA-G on DC and these cells can probably prevent unexpected immune responses in vivo


Subject(s)
Humans , /pharmacology , CD4-Positive T-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/immunology , Dendritic Cells/drug effects , Dendritic Cells/immunology , B7-2 Antigen/metabolism , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Interleukin-17/metabolism , Interleukin-6/metabolism
3.
Article in English | IMSEAR | ID: sea-135586

ABSTRACT

Background & objective: DCs trigger both innate and adaptive immune responses to control HIV infection and represent a viral reservoir acting as target and HIV carriers for infection of permissive CD4+ T-cells. DCs thus form a very attractive study subject to further our existing knowledge of HIV induced immunopathogenesis due to its diverse and crucial role in HIV infection establishment, viral dissemination, immune evasion, viral persistence, etc. We aimed to characterize the effect of HIV infection on myeloid and plasmacytoid dendritic cell subsets in a group of HIV-1 subtype C infected treated or untreated Indian individuals. Methods: Blood DC subset numbers and immunophenotype were studied for 79 HIV infected subjects at various stages of disease and compared with 13 HIV-uninfected controls. Comparisons were also made between groups of subjects based on their CD4+ T cell counts and also experience of antiretrovirals. Results: Significant decreases were observed in blood DC counts and the two DC subsets in HIV infected individuals. Subjects with lowest CD4+ T cell counts also had a drastically reduced DC subset pool which correlated positively with plasma viraemia and negatively with CD4+ T cell counts. DC subsets from HIV infected subjects showed higher expression of co-stimulatory molecules CD40 and CD86, and HIV-1 co-receptors CXCR4 and CCR5 which correlated positively with HIV-1 plasma viraemia. The alterations in blood DCs were partly resolved in ART receiving study subjects. Interpretation & conclusions: Correlation between DC subset activation state and viraemia supports the role of DC activation on viral replication and CD4+ T cell depletion.


Subject(s)
Adult , CD40 Antigens/metabolism , B7-2 Antigen/metabolism , CD4-Positive T-Lymphocytes/cytology , Cell Count , Dendritic Cells/cytology , Dendritic Cells/metabolism , Female , Flow Cytometry , HIV Infections/blood , HIV Infections/immunology , HIV-1 , Humans , Immunophenotyping , India , Male , Middle Aged , Receptors, CCR5/metabolism , Receptors, CXCR4/metabolism , Statistics, Nonparametric , Viremia/blood
4.
Article in English | IMSEAR | ID: sea-17906

ABSTRACT

BACKGROUND & OBJECTIVE: Activation of T cells is mediated through two critical signals provided by activated macrophages. The first signal is triggered when T cell receptor (TCR) binds to the major histocompatibility antigen (MHC/Ag) complex. The second signal is the interaction of co-stimulatory molecules with their respective ligands on T cells for their activation and proliferation. We undertook this study to observe the modulation in B7.1 (CD80) and B7.2 (CD86) co-stimulatory molecules on Mycobacterium tuberculosis infected monocyte derived macrophages (MDM) and their role in T helper (Th1) cell apoptosis. METHODS: M. tuberculosis clinical strains (S7 and S10) and laboratory strains (H37Ra and H37Rv) were used to infect the MDMs. The modulation of apoptosis was assessed by treating T cells with anti-CD3 and anti-CD28 antibodies. The infected MDMs were co-cultured with autologous PPD pulsed T cells to ascertain the role of co-stimulatory molecules during infection. RESULTS: In infected MDMs, all strains on day 1 but only S7 on day 2 showed significant decrease (P<0.05) in B7.1 expression compared to uninfected. The expression levels of B7.2 were also low on day 1 in S7, S10 and H37Ra infected MDMs. The anit-CD3 induced apoptosis in PPD pulsed Tcells showed further reduction with anti-CD28 antibodies. However, the modulation observed in B7.1 expression in infected MDMs was not reflected in T cell apoptosis in co-culture experiments. INTERPRETATION & CONCLUSION: Our results confirmed the role of B7.1 in rescuing the activated Tcells from undergoing apoptosis. During infection when the expression of B7.1 is downregulated, other co-stimulatory molecules may take over its crucial role to confer protective immune response against M. tuberculosis.


Subject(s)
B7-1 Antigen/metabolism , B7-2 Antigen/metabolism , Apoptosis/immunology , Cells, Cultured , Coculture Techniques , Humans , Macrophages/cytology , Mycobacterium tuberculosis/immunology , Th1 Cells/cytology
5.
Experimental & Molecular Medicine ; : 72-84, 2006.
Article in English | WPRIM | ID: wpr-43452

ABSTRACT

Several myeloid leukemia-derived cells have been reported to possess the ability to differentiate into dendritic cells (DC). MUTZ-3, a myeloid leukemia cell line, responds to GM-CSF, IL-4 and TNF-alpha, and acquires a phenotype similar to immature monocyte-derived DC (MoDC). In the present study, MUTZ-3-derived DC (MuDC) showed high level expression of HLA class II molecules, CD80 and CD86, and were able to function as potent antigen presenting cells as previously reported. Interestingly, MuDC maturation was induced by CD40-mediated stimulation, but not by LPS stimulation. We analyzed CCR1, CCR7 and Toll-like receptor (TLR) expressions in MuDC, and measured IL-10 and IL-12 production after maturation stimuli. Although MuDC expressed the mRNA for TLR4, a major component of the LPS receptor system, they did not show an enhanced level of CCR7 or cytokine production after LPS stimulation. In contrast, they responded to CD40 stimulation, which resulted in increased levels of CD83, CD86 and CCR7. Moreover, while LPSstimulated MoDC could potently stimulate NK cells in a DC-NK cell co-culture, LPS-stimulated MuDC failed to stimulate primary NK cells. Taken together, our findings suggest that, although MuDC express TLR4, unlike TNF-alpha and IL-1beta, LPS does not stimulate MuDC to acquire mature phenotypes, and they may have impaired activity to initiate innate immune response.


Subject(s)
Humans , CD40 Antigens/metabolism , B7-1 Antigen/metabolism , B7-2 Antigen/metabolism , Blotting, Western , CD40 Ligand/metabolism , Cell Differentiation , Cell Line, Tumor , Coculture Techniques , Dendritic Cells/drug effects , Enzyme-Linked Immunosorbent Assay , Fluorescein-5-isothiocyanate , Fluorescent Antibody Technique, Indirect , Fluorescent Dyes , Interleukin-10/analysis , Interleukin-12/analysis , Killer Cells, Natural/metabolism , Leukemia, Myeloid/pathology , Lipopolysaccharides/pharmacology , Mitogen-Activated Protein Kinase 3/metabolism , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Toll-Like Receptor 4/metabolism , Tumor Necrosis Factor-alpha/pharmacology , p38 Mitogen-Activated Protein Kinases/metabolism
6.
Experimental & Molecular Medicine ; : 524-532, 2005.
Article in English | WPRIM | ID: wpr-191499

ABSTRACT

Receptor activator of NFkappaB ligand (RANKL) is known as a key regulator of osteoclastogenesis. However, the fact that fibroblasts and periodontal ligament cells express RANKL in response to bacterial substances, suggests that RANKL may have evolved as a part of the immunity to infection. As RANKL increases the survival and activity of dendritic cells, it may have similar effects on macrophages. To address this issue, we studied the effect of RANKL on various functions of macrophages using mouse bone marrow derived macrophages. RANKL enhanced the survival of macrophages and up-regulated the expression of CD86. RANKL-treated macrophages showed increased allogeneic T cell activation and phagocytic activity compared to control cells. In addition, RANKL increased the expression of TNFalpha, MCP-1, and IL-6 but not of IL-10, IL-12, IFN-gamma, and iNOS. Collectively, RANKL augmented the activity of macrophages especially as antigen presenting cells, suggesting its new role in immune regulation.


Subject(s)
Animals , Mice , Antigen-Presenting Cells/cytology , B7-2 Antigen/metabolism , Carrier Proteins/pharmacology , Cell Death/drug effects , Cell Survival/drug effects , Cells, Cultured , Cytokines/metabolism , Flow Cytometry , Histocompatibility Antigens Class II/metabolism , Inflammation Mediators , Interferon-gamma/pharmacology , Lipopolysaccharides/pharmacology , Macrophages/cytology , Membrane Glycoproteins/pharmacology , Mice, Inbred C57BL , Mice, Inbred ICR , Nitric Oxide Synthase Type II/metabolism , Phagocytosis/drug effects , T-Lymphocytes/immunology , Up-Regulation/drug effects
7.
Experimental & Molecular Medicine ; : 567-574, 2005.
Article in English | WPRIM | ID: wpr-191494

ABSTRACT

CD40 ligand (CD40L) expressed by activated CD4+ T cells is a family member of membrane bound TNF family ligand and its interaction with CD40 expressed in APC has been shown to contribute in enhancing immune response. Exogenous stimulation through CD40 has been performed using soluble trimeric CD40L, anti-CD40 monoclonal antibody and cells expressing CD40L. Schneider 2 (S2) cells, a cell line derived from Drosophila melanogaster, was transfected with a plasmid vector, pAc5.1/V5-HisA, for the constitutive expression of CD40L (S2-CD40L). Upon incubation of S2-CD40L with B-lymphocytes for 6 days, activated B cells were examined by counting B cell numbers and for activation markers including CD86 and HLA Class II molecules. The activated B cells were tested for its efficient APC function by mixed lymphocyte reactions (MLR) and enzyme-linked Immunospot (ELISPOT) assay. S2-CD40L was cultured for a year and maintained CD40L expression (>90%). S2-CD40L induced B cell activation as demonstrated by increment of total B cells and up-regulation of CD86 and MHC Class II molecules. Activated B cells pulsed with peptide from human cytomegalovirus pp65 antigen efficiently induced both proliferation and IFN-gamma secretion of T cells. Our result suggests that S2-CD40L can efficiently and conveniently generate B cells as a functional APC and represents a potential role for B-cell mediated cancer immunotherapy.


Subject(s)
Animals , Humans , Antigen Presentation/immunology , B7-2 Antigen/metabolism , B-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/immunology , CD40 Ligand/genetics , Cell Line , Cell Proliferation , Coculture Techniques , Drosophila melanogaster , Gene Expression , Histocompatibility Antigens Class II/metabolism , Lymphocyte Activation , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL